Market Overview - The Hong Kong stock market indices collectively rose, with the Hang Seng Index increasing by 0.68% to 24,902.53 points, the Hang Seng Tech Index up by 0.73%, and the State-Owned Enterprises Index rising by 0.65% [2] Biopharmaceutical Sector - The biopharmaceutical sector showed strong performance, with Junshi Biosciences rising over 33% following a report from CCTV on July 31, stating that the National Healthcare Security Administration supports the clinical application and pricing of new technologies like brain-computer interfaces [4] - Junshi Biosciences' stock price reached 32.180, reflecting a 33.75% increase [5] Steel Industry - The steel sector saw significant gains, with Maanshan Iron & Steel Co. rising over 15%. Despite challenges such as supply-demand imbalances, the industry is expected to maintain stable demand due to supportive policies and ongoing infrastructure investments [4] - Maanshan Iron & Steel Co.'s stock price was reported at 2.530, marking a 15.53% increase [6] Apple-Related Stocks - Apple-related stocks experienced an uptick, with BYD Electronics rising over 7%. Apple's third-quarter revenue growth was reported at 9.6%, reaching $94 billion, which is the fastest growth in nearly three years, exceeding Wall Street expectations [6] - BYD Electronics' stock price was noted at 35.420, with a 7.73% increase [7] Automotive Sector - The automotive sector faced a pullback, with NIO's stock declining over 6%. Recent sales data revealed that Leap Motor achieved over 50,000 monthly sales, while NIO delivered only 21,000 vehicles, placing it near the bottom of the sales rankings [8] - NIO's stock price was recorded at 35.700, reflecting a decrease of 6.54% [8]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688180 | 君实生物 | 39.46 | 4.78% | 19.60万 | 7.55 Z | | 688185 | 康希诺 | 83.37 | 4.21% | 6.30万 | 5.27亿 | | 688293 | 奥浦迈 | 59.34 | 4.11% | ● 1.86万 | 1.10亿 | | 300142 | 沃森生物 | 13.59 | 3.82% | 120.51万 | 16.64亿 | | 000518 | *ST四环 | 2.32 | 2.20% | 12.03万 | 2773.23万 | | 688331 | 荣昌生物 | 63.70 | 1.84% | 7.96万 | 5.03亿 | | 002581 | ST未名 | 7.33 | 1.52% | 9.13万 | 6696.70万 | | 002773 | 康弘药业 | 42.06 | 1.50% | 10.14万 | 4.24亿 | | 300841 | 康华生物 | 78 ...

Market Overview - The three major indices in Hong Kong collectively rose, with the Hang Seng Index increasing by 0.68% to 24,902.53 points, the Hang Seng Tech Index rising by 0.73%, and the State-Owned Enterprises Index up by 0.65% [3]. Biopharmaceutical Sector - Biopharmaceutical stocks showed strong performance, with Junshi Biosciences surging over 33% [2][4]. The National Healthcare Security Administration announced support for new technologies like brain-computer interfaces to enter clinical use and be charged, establishing a pricing mechanism for newly listed drugs [2]. Steel Industry - The steel sector saw significant gains, with Maanshan Iron & Steel Co. rising over 15% [5][6]. Despite challenges such as supply-demand imbalances, the industry is expected to maintain stable demand due to ongoing "stability growth" policies, real estate stabilization, and increased infrastructure investment [5]. Apple-Related Stocks - Apple-related stocks experienced an uptick, with BYD Electronics rising over 7% [7][8]. Apple's third fiscal quarter revenue growth was reported at 9.6%, the fastest in nearly three years, reaching $94 billion, exceeding analysts' expectations [7]. Automotive Sector - The automotive sector faced a pullback, with NIO declining over 6% [9][10]. New energy vehicle sales showed a shift, with Leap Motor achieving over 50,000 monthly sales for the first time, while NIO delivered only 21,000 vehicles [9].

港股三大指数延续昨日反弹行情，南下资金净买入港股超220亿港元！截止收盘，恒生指数涨0.68%， 国企指数涨0.65%，恒生科技指数涨0.73%。盘面上，大型科技股走势分化，其中，快手涨近3%，腾讯 涨1.64%，网易涨1.55%，小米、阿里巴巴、百度、美团仍旧飘绿；生物医药股再度迎来大涨行情，君 实生物尾盘快速拉升大幅上涨近34%表现十分抢眼，康诺亚、复宏汉霖、诺诚健华、药明康德皆走强； 纸企龙头发起新一轮涨价潮，纸业股拉升明显，晨鸣纸业大涨近15%刷新阶段新高；近期行业利好袭 来，脑机接口概念股普遍上涨，南京熊猫电子盘中涨至8%，钢铁股、苹果概念股、濠赌股、核电股、 重型机械股、航空股、保险股、内银股、煤炭股多数表现活跃。另一方面，7月新能源车销量成绩单发 布，汽车股涨跌不一，蔚来汽车、零跑汽车、比亚迪股份全天表现低迷，半导体股午后走低，中芯国际 转跌近1%，锂电池股、教育股、石油股少部分走低。(格隆汇) ...

华泰证券发布港股策略研报称，近期港股回调主因内外预期修正，但中期流动性宽松逻辑不改。配置上 建议寻找景气改善+低估值板块，尤其强调对科技板块的配置；短期交易围绕中报业绩展开，建议关 注：估值有性价比且景气改善的游戏和互联网电商龙头；前向12个月估值分位数略高但盈利兑现度高， 如港股创新药及非银金融。 平安证券(香港)研究也指出，当前港股市场仍具有较低估值以及"赚钱效应"下的交易渐趋活跃等优势， 中长期走势仍可保持乐观展望。建议继续关注人工智能、机器人、半导体、工业软件等新质生产力等科 技板块，及政策加力支持的创新医药板块以及具有消费属性的中医药和医疗板块。 金融界8月5日消息 截至收盘，港股恒生指数涨0.68%，报24902.53点，恒生科技指数涨0.73%，报 5521.07点，国企指数涨0.65%，报8951.07点，红筹指数涨0.53%，报4228.54点，南向资金净买入超234 亿港元，君实生物涨超33%，东方甄选涨超16%，山东墨龙涨超14%，比亚迪电子涨超7%，大型科技股 中，阿里巴巴-W跌0.17%，腾讯控股涨1.64%，京东集团-SW平收，小米集团-W跌0.46%，网易-S涨 1.55%，美团 ...

Group 1 - The stock price of Junshi Biosciences (01877) surged nearly 35%, reaching HKD 32.28 with a trading volume of HKD 1.25 billion [1] - Guotai Junan Securities reported a growing enthusiasm for dual-antibody development globally, indicating a window for innovative achievements in the domestic antibody industry [1] - Junshi Biosciences has extensive experience in monoclonal antibody development, with its PD-1 monoclonal antibody, Toripalimab, being one of the first domestically launched PD-1 inhibitors [1] Group 2 - Toripalimab is currently approved for multiple indications in China and is expanding its global commercialization network, with approvals expected in the US and EU in 2023 and 2024 [1] - The company has developed a series of innovative dual-antibody molecules (JS207, JS201, JS203, JS205) and dual-antibody ADCs (JS212) [1] - On June 20, Junshi Biosciences completed a placement of 41 million new shares, raising approximately HKD 1.026 billion, with 70% of the funds allocated for innovative drug research and 30% for general corporate purposes [1]

本文源自：金融界 作者：行情君 8月5日，君实生物(01877)盘中上涨32.83%，截至15:54，报31.96元/股，成交11.06亿元。 上海君实生物医药科技股份有限公司主要业务是发现、开发和商业化创新疗法，特别是在肿瘤免疫疗 法、自身免疫系统疾病、慢性代谢类疾病、神经系统疾病、感染类疾病等治疗方面。公司拥有卓越的创 新药物发现能力、先进的生物技术研发、全产业链大规模生产技术和极具市场潜力的在研药品组合。 截至2025年一季报，君实生物营业总收入5.01亿元、净利润-2.35亿元。 ...

港股君实生物拉升，一度涨超30%。 ...

每经AI快讯，8月5日，港股君实生物拉升，一度涨超30%，现涨24%。 （文章来源：每日经济新闻） ...

Core Insights - The healthcare ETF, Taikang (159760), has shown a slight increase of 0.46%, tracking the National Public Health and Healthcare Index (980016), which rose by 0.48% [1] - A new pricing mechanism for newly launched drugs has been established by the National Healthcare Security Administration, allowing high-level innovative drugs a five-year price stability period, which is expected to reverse the trend of price drops upon market entry [1] - Innovative drugs like Zebutinib from BeiGene and the dual-antibody drug from Baillie Tianheng are anticipated to drive significant revenue growth in the coming years [1][2] Industry Developments - The index constituents are experiencing a technological breakthrough, with companies like Kangfang Bio and Eli Lilly making significant advancements in drug development [2] - The AI+mRNA platform developed by CloudTop has achieved full-chain coverage from antigen design to industrial production, indicating a shift in innovative drug development paradigms [3] - The index includes companies that are directly benefiting from healthcare payment reforms and supportive policies for innovative drugs, with over 80% of the constituents poised to gain from these changes [4] Financial Performance - As of June 30, 2025, the top ten weighted stocks in the National Public Health and Healthcare Index accounted for 51.67% of the index, with companies like WuXi AppTec and Hengrui Medicine leading the way [5] - Hengrui Medicine's R&D investment ratio reached 28% in the first half of 2025, with a 50% year-on-year increase in the number of new drug approvals, indicating strong growth potential [4] Market Outlook - The healthcare ETF is expected to continue leading in the structural market of the healthcare industry, driven by the expansion of commercial insurance innovative drug catalogs and accelerated approvals for AI medical devices [4] - The index reflects the performance of listed companies in the public health and healthcare sector, focusing on prevention, testing, and treatment areas with significant potential for AI technology applications [4]